Eplerenone in patients with systolic heart failure and mild symptoms.

By F. Zannad, J. McMurray, H. Krum, D. V. van Veldhuisen, K. Swedberg, Harry Shi, J. Vincent, Stuart J. Pocock, B. Pitt. New England Journal of Medicine, 2011

2,866 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/549ade77fcefbd2ca3e41f4a9c28d247e840cd79

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. G. Fonarow
2. Philippe van de Borne
3. Xiaobo Mao
4. Gui-wen Yi
5. T. Horwich
6. Jeroen J. Bax
7. Helmut Baumgartner
8. Paulus Kirchhof

In Endocrinology, Diabetes and Metabolism

1. Philippe van de Borne
2. F. Cosentino
3. Joshua A. Beckman
4. F. Paneni
5. M. Creager
6. Véronique L. Roger

Citations in the corpus

• 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the preventionof sudden cardiac death (2015, positive): “In the most recent trial involving eplerenone, 20% of patients also had an implanted device (ICD or CRT), but the drug was equally effective in patients with as in those without device therapy.(309) This beneficial effect of MRAs on the incidence of SCD in patients with LV systolic dysfunction was c”
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, background): “EF indicates ejection fraction; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; and HFrEF, heart failure with reduced ejection fraction.”